This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Pirtobrutinib inhibits wild-type and mutant Bruton’s tyrosine kinase-mediated signaling in chronic lymphocytic leukemia
Blood Cancer Journal Open Access 20 May 2022
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hendriks RW, Yuvaraj S, Kil LP . Targeting Bruton's tyrosine kinase in B cell malignancies. Nat Rev Cancer 2014; 14: 219–232.
Rawlings DJ, Witte ON . The Btk subfamily of cytoplasmic tyrosine kinases: structure, regulation and function. Semin Immunol 1995; 7: 237–246.
Nisitani S, Satterthwaite AB, Akashi K, Weissman IL, Witte ON, Wahl MI . Posttranscriptional regulation of Bruton's tyrosine kinase expression in antigen receptor-stimulated splenic B cells. Proc Natl Acad Sci USA 2000; 97: 2737–2742.
Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014; 371: 213–223.
Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med 2015; 373: 2425–2437.
Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013; 31: 88–94.
Burger JA, Kipps TJ . CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006; 107: 1761–1767.
Chen SS, Chang BY, Chang S, Tong T, Ham S, Sherry B et al. BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia. Leukemia 2016; 30: 833–843.
Cervantes-Gomez F, Lamothe B, Woyach JA, Wierda WG, Keating MJ, Balakrishnan K et al. Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic leukemia. Clin Cancer Res 2015; 21: 3705–3715.
Acknowledgements
We thank Benjamin Hayes and Mark Nelson for coordinating sample distribution during therapy. This work was supported in part by MD Anderson CLL Moon Shot Program and Sponsored Research Agreement form Pharmacyclics, Inc.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
VG has a sponsored research agreement with Pharmacyclics, Inc. Other authors do not have any conflict of interest.
Rights and permissions
About this article
Cite this article
Cervantes-Gomez, F., Kumar Patel, V., Bose, P. et al. Decrease in total protein level of Bruton’s tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes. Leukemia 30, 1803–1804 (2016). https://doi.org/10.1038/leu.2016.129
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2016.129
This article is cited by
-
Pirtobrutinib inhibits wild-type and mutant Bruton’s tyrosine kinase-mediated signaling in chronic lymphocytic leukemia
Blood Cancer Journal (2022)
-
Population Pharmacokinetics of Ibrutinib and Its Dihydrodiol Metabolite in Patients with Lymphoid Malignancies
Clinical Pharmacokinetics (2020)